The relationship of the angiogenesis regulators VEGF-A, VEGF-R1 and VEGF-R2 to p53 status and prognostic factors in epithelial ovarian carcinoma in FIGO-stages I–II

Abstract

The aim of this study was to evaluate prognostic effect of the angiogenesis regulators VEGF-R1, VEGF-R2 and VEGF-A for recurrent disease and disease-free survival (DFS), and their relation to the apoptosis regulator p53, in 131 patients with FIGO-stages I–II with epithelial ovarian cancer. For the detection of positivity of the markers the techniques of tissue microarrays and immunohistochemistry (IHC) were used. In tumors the frequency of positive staining for VEGF-R1 was 19%, for VEGF-R2 and VEGF-A, it was 77 and 70%, respectively. Positivity for p53 was detected in 25% of tumors. The total number of recurrences in the complete series was 34 out of 131 (26%) and 5-year disease-free survival (DFS) was 68%. Positive staining for VEGF-A (P=0.030), VEGF-R2 (P=0.011) and p53 (P=0.015) was found more frequently in type II tumors than in type I tumors. Patients with VEGF-R1 negative tumors had worse (P=0.021) DFS compared to patients with VEGF-R1 positive tumors. In two multivariate Cox analyzes with DFS as endpoint, FIGO-stage (HR=3.8), VEGF-R2 status (HR=0.4) and p53 status (HR=2.3), all were significant and independent prognostic factors. When the variables VEGF-R2 and p53 were replaced with the new variable VEGF-R2+p53−/other three combinations in one group, it was found that patients from that subgroup had 86% reduced risk of dying in disease (HR=0.24). Findings above, confirmed relationship between VEGF-R2 and VEGF-A and p53, respectively, with regard to recurrent disease and survival. Some findings from the present study are different from results from previous studies on the regulation of angiogenesis. Despite many trials with anti-angiogenic agents in the front line of ovarian cancer have shown to be positive for progression-free survival, no one has demonstrated an impact on overall survival. Therefore, one of the greatest challenges in ovarian cancer research, is to discover predictive and prognostic biomarkers.

Immunohistochemical Expression of Glut-1 in Epithelial Ovarian Tumors: Correlation With the Clinicopathological Factors and Tumor Proliferative Marker Pcna.

“…Furthermore, analysis of Glut-1 expression among the studied ovarian carcinomas, detected that Glut-1 tend to be expressed more intensely in tumors with advanced FIGO stage (Stage III-IV) with a statistically significant relationship (p=0.005). This is consistent with many previous related studies [24,28,33,36, and 37].…”

Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients

“…Our studies showed that in this group of patients the concentrations of VEGF receptor, VEGFR2 proved to be an independent prognostic factor for OS. Most recent literature data presents results of studies on the relationship between the expression of VEGF, its receptors and recognized clinicopathological factors, and their role in the prognosis of the disease [ 24 , 25 ]. Among numerous analyzed clinicopathological features, the authors have observed only a trend of relationship between the expression of VEGFR2 and the degree of cell differentiation (G), but no association was shown between the expression of VEGF-R2 and survival of patients with EC, however, not taking into account the type of neoplasm [ 26 ].…”

Quantitative analysis of the human ovarian carcinoma mitochondrial phosphoproteome

“…VEGF is a specific heparin-binding growth factor of vascular endothelial cells, which can induce angiogenesis in vivo . At the same time, VEGF can increase vascular permeability and mobility of cancer cells, induce tumor angiogenesis, and maintain the growth of tumors [20]. Here, the new biomarkers that were found in the VEGF signaling included phosphorylations of CAV1 at residue S 6 (fold change = 0.03, p = 8.07E-07), CAV1 at residue S 26 (fold change = 0.06, p = 9.35E-09), CTNNA1 at residue S 518 (fold change = 0.78, p = 1.00E-04), HSP90 at residue S 217 (fold change = 0.80, p =2.83E-02), CFL1 at residue S 3 (fold change = 0.29, p = 8.00E-05), and MYH9 at residue S 1943 (fold change = 1.40, p = 7.70E-03), which might be novel molecules and regulation mechanism for tumor angiogenesis.…”